Đặt lịch khám

PROTECT CHILDREN FROM EARLY RSV WITH BEYFORTUS (NIRSEVIMAB) ANTIBODY

PROTECT CHILDREN FROM EARLY RSV WITH BEYFORTUS (NIRSEVIMAB) ANTIBODY

04/11/2025

Respiratory Syncytial Virus (RSV) is a leading cause of pneumonia, bronchiolitis, and severe respiratory failure in infants and young children. Currently, the American International Hospital (AIH) has implemented the administration of Sanofi's (France) monoclonal antibody Beyfortus (Nirsevimab). This solution helps prevent RSV, protecting babies from their first months of life.

Beyfortus (scientific name is Nirsevimab) is a monoclonal antibody for RSV prevention specifically designed for infants and young children. Unlike vaccines, Beyfortus directly transmits passive immunity to the baby, helping the baby's body fight against the RSV immediately after injection, without needing to wait for antibody production time like conventional vaccines.

Beyfortus's protective mechanism 

Beyfortus is a long-acting IgG1 antibody that works by specifically binding to the F protein of the RSV virus, preventing the virus from entering the baby's respiratory cells. As a result, the baby is protected from the risk of RSV infection throughout the epidemic season – the time when the virus is most easily spread.

Which children should receive Beyfortus?

  • Newborns and infants during their first RSV season, including both full-term and pre-term infants. 

  • Children under 24 months of age at high risk for recurrent RSV, such as those with congenital heart disease, chronic lung disease, or extreme prematurity.

Proven efficacy

According to large clinical studies (MELODY Trial – NEJM 2022, CDC & WHO 2024), Beyfortus helps:

  • Significantly reduce RSV-related hospitalizations. 

  • Reduce cases requiring intensive care due to RSV. 

  • Protective efficacy lasts approximately 6 months (equivalent to 1 RSV season), and some studies have recorded efficacy up to 361 days. 

High safety

Beyfortus has been proven safe and well-tolerated in young children. Post-injection reactions are usually mild and transient, including:

  • Mild pain, redness, or swelling at the injection site. 

  • Mild fever or slight fussiness in the baby.

Serious reactions are very rare, similar to the placebo group. Additionally, Beyfortus can be administered simultaneously with other vaccines.

Reference dosage

  • Children <5 kg: 50 mg (intramuscular injection, 1 single dose)

  • Children ≥5 kg: 100 mg (intramuscular injection, 1 single dose). 

  • High-risk children in their second RSV season: 200 mg (divided into 2 separate 100 mg injections).

At American International Hospital (AIH), we are committed to using high-quality medicines with clear origins and ensuring safe storage and usage procedures when vaccinating customers. For more detailed information about monoclonal antibodies for RSV prevention and a vaccination schedule suitable for each age group, please contact Hotline 1900 3399 or inbox https://m.me/aih.com.vn for consultation.

--------------------

AMERICAN INTERNATIONAL HOSPITAL (AIH):
☎ Hotline: 1900 3399 || (028) 3910 9999​
🌏 Website: www.aih.com.vn
📍Address: (Entrance from 199 Nguyen Hoang Street) No.6, Bac Nam 3 Street, Binh Trung Ward, Ho Chi Minh
  • bởi Admin AIH
  • Danh mục: Tin tức & Sự kiện

Để lại bình luận

Tin tức